We are transparent about our clinical trials' results

As a patient-centric company, we are transparent about our clinical trials' results, so that we can enable patients and healthcare professionals to make informed decisions about treatment.

Our commitments apply to interventional clinical trials (incl. drug-device combination trials) sponsored by LEO Pharma and they currently meet, and in some cases exceed, existing requirements from authorities and major industry associations regarding disclosure of clinical trials


Our undertakings for increased clinical trial transparency carefully take the confidentiality of our trial participants into account and their anonymity is maintained by protection of sensitive information.


Registration of clinical trials

 

LEO Pharma registers all interventional clinical trials in the global US-based public data registry (http://www.clinicaltrials.gov), including Phase 1 trials. The trials get registered before enrolment of trial participants.


We also register trials in the EU Clinical Trials Register (EU CTR; http://www.clinicaltrialsregister.eu) and in various national registries, when required, and in addition, our clinical trials can be found on the WHO Clinical Trials Registry Platform (http://www.who.int/trialsearch).


Reporting of clinical trial results


LEO Pharma considers result reporting of clinical trials to be an ethical and scientific responsibility. By ensuring that all our clinical results are accessible, we minimise the risk for biased and selective reporting.


A fundamental component of LEO Pharma’s endeavours for increased clinical trial transparency is to guarantee return of clinical trial results to the patients. Our trial participants are informed where and when the trial results will become available as well as that we express our sincere gratitude in writing for their valuable contributions.


Public data registries


The clinical trial results of LEO Pharma are reported according to applicable laws and regulations and international recommendations in:



Reporting is performed after completion or termination of the clinical trial and the results of the trial are reported regardless of outcome.


LEO Pharma’s corporate website


Posting of results on LEO Pharma’s corporate website comprises clinical trials in healthy subjects and patients and covers Phases 1 – 4. These clinical trial results are posted in two formats:


  • Clinical trial reports, excluding appendices
  • Clinical trial report synopses (i.e. short report summaries)

Results are posted for trials dating back to 1990* as outlined below.


The synopses are posted within 12 months after trial completion. However, for paediatric clinical trials synopses are publicly disclosed within 6 months. The clinical trial reports from trials investigating approved products in approved indications are posted after the results have been presented in an original research article in a peer-reviewed journal.


Peer-reviewed journals


LEO Pharma seeks publication of all Phase 3 clinical trials in peer-reviewed journals within 18 months of trial completion, regardless of whether the findings are positive or negative. Results from exploratory and post-hoc analyses, and clinical trials outside Phase 3, will be published if deemed scientifically or medically important.


Hyperlinks to the peer-reviewed journals publishing results from our clinical trials from 2014* and onwards are made available on LEO Pharma’s clinical trial disclosure website


Disclosure of clinical documentation in market authorisation applications


LEO Pharma complies with current regulatory requirements to publicly disclose submission documentation being part of authorisation applications.


Access to anonymised data from trials in approved products and discontinued projects


LEO Pharma recognises that new scientific discoveries can be made from existing data sources, including the individual patient-level data from our clinical trials. We support clinical research and encourage the use of our data to expand the understanding of and ability to treat dermatological and other diseases.


It is thus possible for external researchers to request access to anonymised patient-level data from clinical trials sponsored by LEO Pharma, investigating approved products in approved indications (trials from 2000* and onwards) or projects where the development has been discontinued (trials from 2014* and onwards). Requests can be made when the clinical trial report has been posted on the corporate website.


LEO Pharma also offers access to anonymised trial-level data, to the extent that the data have been prepared for the clinical trial report.


The Patient and Scientific Review Board


The evaluation of the data request and the decision on access to data is made by the external Patient and Scientific Review Board. The Patient and Scientific Review Board comprise three highly experienced scientists while two seats are allocated to representatives of patient associations.


The Patient and Scientific Review Board evaluate whether the research proposal has a valid scientific rationale, is non-commercial, and is in the best interest of patients. The decision by the Patient and Scientific Review Board is made independently of LEO Pharma. For detailed information on the composition and processes of the Board, see its Charter.

International clinical trials in in-licensed or acquired products

We fulfil our regulatory responsibilities as sponsor of clinical trials as well as marketing authorisation holder of approved medicines for our entire clinical research and product portfolio.


However, we cannot guarantee that our disclosure commitments can be applied on all the clinical trials investigating in-licenced and acquired products for which LEO Pharma has not sponsored the trials, except for those for which we have been involved in the initial marketing authorisation application process of the product (in any territory).


In case of questions, contact disclosure@leo-pharma.com 


For more information, visit our LEO Pharma’s clinical trial disclosure website